Emily Waltz, for IEEE Spectrum, writes about rHEALTH's first regulatory clearance and implications of the technology for developments in consumer-driven, biomedical diagnostics. Recently, rHEALTH achieved CE marking of its Fluorogenic Factor VIII (FVIII) Test Kit for professional use and met the requirements of CD 98/79/EEC (the European IVD Directive).
Read more at IEEE Spectrum: https://spectrum.ieee.org/the-human-os/biomedical/diagnostics/moving-blood-tests-from-the-lab-to-the-consumer